YS Biopharma Co. Ltd. Ordinary Shares Company Overview

YS Biopharma Co. Ltd. Ordinary Shares logo
YS Biopharma Co. Ltd. Ordinary Shares
Invesco QQQ Trust primary media

About YS Biopharma Co. Ltd. Ordinary Shares

YS Biopharma (NASDAQ: YS) is a biopharma company listed on the NASDAQ stock exchange. The company focuses on developing, manufacturing, and commercializing innovative vaccines and therapeutic products. Key projects include its flagship PIKA adjuvant technology and a pipeline of next-generation vaccines targeting infectious diseases like COVID-19 and rabies. The main objectives are to improve global health through cutting-edge vaccines and to expand its product portfolio via research and development. YS aims to leverage its scientific expertise to address unmet medical needs and enhance the effectiveness of existing and new vaccines.

What is YS Biopharma Co. Ltd. Ordinary Shares known for?

Snapshot

2010
Year founded
773
Employees
Beijing, China
Head office
Loading Map...

Operations

All Locations
People’s Republic of China

Produtos e/ou serviços de YS Biopharma Co. Ltd. Ordinary Shares

  • Pneumococcal Conjugate Vaccine: A key product designed to prevent pneumococcal infections, critical for immunization programs, particularly in children.
  • Ebola Vaccine: Focuses on providing a robust solution for Ebola virus prevention, pivotal for controlling outbreaks in affected regions.
  • Hepatitis B Vaccine: Essential for combating hepatitis B infections with strong immunogenicity, aimed at lowering global disease prevalence.
  • Rabies Vaccine: Offers reliable post-exposure prophylaxis against rabies, vital for both human and veterinary use.
  • Animal Vaccines: Broad range of vaccines targeting livestock diseases, enhancing animal health and agricultural productivity.
  • Research and Development: Continuous efforts in innovative vaccine development, emphasizing future health solutions and technological advancements.

equipe executiva do YS Biopharma Co. Ltd. Ordinary Shares

  • Mr. Gang LiHead of Marketing & Sales
  • Dr. Yuan Liu Ph.D.Head of Vaccine Research
  • Dr. Hui Shao Ph.D.President, CEO & Executive Director
  • Ms. Chunyuan Wu CPAChief Financial Officer & Director
  • Dr. Zenaida Reynoso MojaresChief Medical Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.